Skip to main content
45kviews
Editorial20 January 2026
Editorial: Cancer biology, immunotherapy and aging
Stephane Koda, Jensen G. Weedorand Parfait Botolo Sakava

Cancer biology, immunotherapy, and aging converge in ways that challenge traditional clinical paradigms (Ontiveros et al. 2023;Kao et al. 2025). As the immune system undergoes age-related remodeling, including immunosenescence, chronic inflammation, stromal alteration, and metabolic shifts, the tumor microenvironment evolves in parallel, producing distinct patterns of tumor progression and therapy response (Erbe et al. 2021;Guegan et al. 2025). Yet, despite older adults comprising the majority of cancer diagnoses, they continue to be underrepresented in clinical research (Kao et al. 2025;Pallis et al. 2010;Berger et al. 2006). Emerging computational and image-based tools, as highlighted by the studies in this Research Topic, provide new opportunities to design age-inclusive strategies and overcome limitations in conventional risk stratification and biological understanding. These contributions collectively map the complex interplay between aging physiology and cancer behavior while showcasing the strengths and weaknesses of current analytical approaches.

integration: machine learning, radiomics,

Several studies in this collection deploy machine learning (ML) to address gaps in traditional clinical prediction models. The differentiated thyroid cancer (DTC) study demonstrates the strength of ensemble algorithms, particularly XGBoost, for capturing nonlinear interactions between clinical variables. Similarly, the breast cancer axillary lymph node burden analysis highlights the value of combining radiomics with ML to extract predictive imaging signatures not discernible through human assessment. These methods show clear advantages in handling high-dimensional data, improving accuracy, and enabling personalized risk estimation. However, a shared limitation emerges: ML models rely heavily on retrospective datasets, are vulnerable to overfitting, and often lack interpretability despite tools like SHAP. External validation, present in some studies but absent in others, remains essential before these tools can be clinically deployed.

The study identifying T-cell exhaustion and macrophage polarization genes in breast cancer leverages multi-omics data integration and machine learning to uncover immune-related prognostic signatures. This contrasts with imaging-driven methods but shares the goal of revealing biological complexity underlying variable clinical outcomes.While this approach offers mechanistic depth not available through radiomics or clinical modeling, it introduces its own constraints, such as variability across datasets, bulk RNAseq limitations (cell-type averaging), and challenges in translating genetic signatures into actionable clinical decision-making.

The glioma and colorectal neuroendocrine neoplasms (CRNEN) studies use traditional regression-based nomograms, long valued for their transparency and clinician usability.Unlike ML models, nomograms allow straightforward bedside application and highlight effect sizes for individual variables. Yet, these model types assume linearity and may oversimplify complex interactions, a trade-off between usability and nuance.Notably, the CRNEN models incorporate a dual predictive-prognostic framework, illustrating how classic methodologies continue to evolve when embedded within large, high-quality datasets.

The TAS-102 case report, while not methodologically complex, fills a crucial evidence gap:real-world therapeutic guidance for frail, multimorbid elderly patients. Such clinical narratives complement computational studies by grounding innovations in practical, human-centered contexts, an essential dimension often absent from data-driven work.Cross-study themes: What do these findings tell us?

Radiomics, machine learning, and transcriptomics each offer a different "lens" through which to view tumor behavior. When integrated, these modalities could enable more accurate, multi-dimensional prediction models that reflect both tumor biology and host factors, particularly in older patients.

Nearly all studies rely on retrospective datasets such as SEER or single-center cohorts.While rich in sample size, these datasets lack functional biomarkers, treatment toxicity data, and geriatric assessments. Prospective, age-inclusive cohorts are urgently needed.

Despite their contributions, the studies share several overarching limitations:1. Retrospective designs introduce selection bias and limit causal inference.2. Lack of functional aging measures: chronological age alone inadequately captures biological aging or treatment tolerance.3. Limited longitudinal data: Few studies examine dynamic changes over time, especially relevant for aging-related biology.4. Sparse diversity in many datasets underrepresents low-income, rural, and minority populations.5. Translational gap: predictive models often lack pathways for real-world implementation in clinics.Addressing these limitations will be essential to ensure that computational advances translate into meaningful clinical impact.

Models incorporating frailty indices, functional status, markers, and patientreported outcomes could dramatically improve prediction accuracy for older adults.

Future studies should explore models that combine:

Predictive models must move beyond validation toward prospective testing, where predictions actively inform treatment choices.

As ML models become more prevalent, transparency, fairness, and bias mitigation will be critical, particularly in elderly populations disproportionately affected by health disparities.

The studies in this research topic collectively demonstrate how emerging analytic tools and biological insights can refine cancer characterization and improve clinical decision-making across diverse tumor types. Yet they also highlight persistent challenges: inadequate agespecific limited external validation, and gaps in real-world applicability. Bridging these divides will require interdisciplinary collaboration, prospective validation, and a deeper commitment to studying cancer through the lens of aging biology.By embracing these directions, the field can move toward genuinely personalized, ageinclusive oncology where innovations in cancer immunotherapy, computational science, and geroscience converge to benefit all patients across the lifespan.

1,261 views

ORIGINAL RESEARCH
8 September 2025
A machine learning model for predicting bone and/or lung metastasis in differentiated thyroid carcinoma: enhancing precision in risk stratification
Libin Huang, 2 more and Shengyin Liao

3,932 views

3 citations

ORIGINAL RESEARCH
27 May 2025
Identification and validation of prognostic genes associated with T-cell exhaustion and macrophage polarization in breast cancer
Fengqiang Cui, 5 more and Nanlin Li

3,496 views

3 citations

Machine learning-driven ultrasound radiomics for assessing axillary lymph node burden in breast cancer
ORIGINAL RESEARCH
27 February 2025
Machine learning-driven ultrasound radiomics for assessing axillary lymph node burden in breast cancer
Si-Rui Wang, 6 more and Ji-Xue Hou
ObjectiveThis study explores the value of combining intratumoral and peritumoral radiomics features from ultrasound imaging with clinical characteristics to assess axillary lymph node burden in breast cancer patients.MethodsA total of 131 breast cancer patients with axillary lymph node metastasis (ALNM) were enrolled between June 2019 and September 2024. Patients were divided into low (n=79) and high (n=52) axillary lymph node burden (ALNB) groups. They were further split into training (n=92) and validation (n=39) cohorts. Intratumoral and peritumoral features were analyzed using the maximum relevance minimum redundancy (MRMR) and least absolute shrinkage and selection operator (LASSO) methods. Six machine learning models were evaluated, and a combined clinical-radiomics model was built.ResultsThe combined logistic regression model exhibited superior diagnostic performance for high axillary lymph node burden, with areas under the ROC curve (AUC) of 0.857 in the training cohort and 0.820 in the validation cohort, outperforming individual models. The model balanced sensitivity and specificity well at a 52% cutoff value. A nomogram provided a practical risk assessment tool for clinicians.ConclusionThe combined clinical-radiomics model showed excellent predictive ability and may aid in optimizing management and treatment decisions for breast cancer patients.

4,364 views

10 citations

G Protein-Coupled Estrogen Receptor 1 (GPER-1) is a membrane estrogen receptor that has emerged as a key player in breast cancer development and progression. In addition to its direct influence on estrogen signaling, a crucial interaction between GPER-1 and the hypothalamic-pituitary-gonadal (HPG) axis has been evidenced. The novel and complex relationship between GPER-1 and HPG implies a hormonal regulation with important homeostatic effects on general organ development and reproductive tissues, but also on the pathophysiology of cancer, especially breast cancer. Recent research points to a great versatility of GPER-1, interacting with classical estrogen receptors and with signaling pathways related to inflammation. Importantly, through its activation by environmental and synthetic estrogens, GPER-1 is associated with hormone therapy resistance in breast cancer. These findings open new perspectives in the understanding of breast tumor development and raise the possibility of future applications in the design of more personalized and effective therapeutic approaches.

5,567 views

8 citations

ORIGINAL RESEARCH
15 January 2025
Comparison of clinicopathological characteristics and prognosis between primary squamous cell carcinoma of the thyroid and squamous cell carcinoma combined with papillary thyroid carcinoma
Wanyun Yan, 4 more and Jiping Su

2,528 views

3 citations

ORIGINAL RESEARCH
7 January 2025
Predictive and prognostic nomogram models for liver metastasis in colorectal neuroendocrine neoplasms: a large population study
Xiao Lei, 8 more and Lijie Song

2,830 views